Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 3/2011

Open Access 01-06-2011 | Research

Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials

Authors: Ritesh Maharaj, Victoria Metaxa

Published in: Critical Care | Issue 3/2011

Login to get access

Abstract

Introduction

Patients undergoing coronary revascularization often require inotropic support that has been associated with an increased risk for death and morbidity. The purpose of this study was to evaluate the effect of levosimendan versus control on survival after coronary revascularization.

Methods

A systemic review and meta-analysis of the literature was carried out on published randomized controlled clinical trials that investigated the efficacy of levosimendan compared to other therapy in patients having coronary revascularisaion. The databases searched were Pubmed, EMBASE, the Cochrane Registry of Clinical Trials and the metaRegister of Controlled Trials. Studies that compared levosimendan to any other therapy for coronary revascularisation in adult humans and reported at least one outcome of interest were considered for inclusion. Both percutaneous coronary intervention and cardiac surgery were included. Data extraction was performed independently by two reviewers using predefined criteria. Relevant outcomes included mortality, cardiac index, cardiac enzymes, length of stay and post-procedural atrial fibrillation.

Results

The meta-analysis included 729 patients from 17 studies. Levosimendan was associated with a mortality reduction after coronary revascularization, (19/386 in the levosimendan group vs 39/343 in the control arm) odds ratio (OR) 0.40 (95% confidence interval (CI) 0.21 to 0.76, P for overall effect 0.005, P for heterogeneity = 0.33, I2 = 12% with a total of 729 patients. Levosimendan also had a favourable effect on cardiac index (standardised mean difference 1.63, 95% CI 1.43 to 1.83, P for overall effect < 0.00001), length of intensive care stay (random effects model, mean difference - 26.18 hours 95% CI 46.20 to 6.16, P for heterogeneity < 0.00001, I2 = 95%, P for overall effect P = 0.01), reductions in the rate of atrial fibrillation (OR 0.54, 95% CI 0.36 to 0.82, P for effect = 0.004, P for heterogeneity 0.84, I2 = 0% for 465 patients) and troponin I levels group (mean difference -1.59, 95% CI 1.78 to 1.40, P for overall effect < 0.00001, P for heterogeneity < 0.00001, I2 = 95%). Limitations of this analysis are discussed.

Conclusions

Levosimendan is associated with a significant improvement in mortality after coronary revascularization. There are also improvements in several secondary endpoints. A suitably powered randomised controlled trial is required to confirm these findings and to address the unresolved questions about the timing and dosing of levosimendan.
Appendix
Available only for authorised users
Literature
1.
Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M: Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009, 102: 198-204. 10.1093/bja/aen367CrossRefPubMed
2.
Lee CH, van Domburg RT, Hoye A, Lemos PA, Tanabe K, Smits PC, van der Giessen WJ, de Feyter P, Serruys PW: Predictors of survival after contemporary percutaneous coronary revascularization for acute myocardial infarction in the real world. J Invasive Cardiol 2004, 16: 627-631.PubMed
3.
Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, White HD, Thompson TD, Topol EJ: Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet 1997, 349: 75-78. 10.1016/S0140-6736(96)03031-0CrossRefPubMed
4.
Pae WE Jr, Miller CA, Matthews Y, Pierce WS: Ventricular assist devices for postcardiotomy cardiogenic shock. A combined registry experience. J Thorac Cardiovasc Surg 1992, 104: 541-552. discussion 552-543PubMed
5.
Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER, Weder W, Follath F: Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 14: 201.
6.
Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A: Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 2001, 15: 306-315. 10.1053/jcan.2001.23274CrossRefPubMed
7.
Fowler MB, Alderman EL, Oesterle SN, Derby G, Daughters GT, Stinson EB, Ingels NB, Mitchell RS, Miller DC: Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation 1984, 70: I103-111.PubMed
8.
Pagel PS: Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application? Anesth Analg 2007, 104: 759-761. 10.1213/01.ane.0000256864.75206.6dCrossRefPubMed
9.
10.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339: b2535. 10.1136/bmj.b2535PubMedCentralCrossRefPubMed
11.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Educ) 2009, 339: b2700. 10.1136/bmj.b2700CrossRef
12.
Reynolds HR, Hochman JS: Cardiogenic shock: current concepts and improving outcomes. Circulation 2008, 117: 686-697. 10.1161/CIRCULATIONAHA.106.613596CrossRefPubMed
13.
Dauerman HL, Goldberg RJ, White K, Gore JM, Sadiq I, Gurfinkel E, Budaj A, Lopez de Sa E, Lopez-Sendon J, Global Registry of Acute Coronary Events. GRACE Investigators: Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002, 90: 838-842. 10.1016/S0002-9149(02)02704-2CrossRefPubMed
14.
Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD: Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006, 295: 2511-2515. 10.1001/jama.295.21.2511PubMedCentralCrossRefPubMed
15.
Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM, Holmes DR Jr: Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 2007, 50: 1752-1758. 10.1016/j.jacc.2007.04.101CrossRefPubMed
16.
Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J: Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009, 119: 1211-1219. 10.1161/CIRCULATIONAHA.108.814947PubMedCentralCrossRefPubMed
17.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010, 362: 779-789. 10.1056/NEJMoa0907118CrossRefPubMed
18.
Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A: Inotropes in cardiac patients: update 2011. Curr Opin Crit Care 2010, 16: 432-441. 10.1097/MCC.0b013e32833e10fbCrossRefPubMed
19.
Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER, Weder W, Follath F: Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010, 14: 201. 10.1186/cc8153PubMedCentralCrossRefPubMed
20.
Guarracino F, Landoni G, Baldassarri R, Nobile L, Stefani M: Concomitant levosimendan and esmolol infusion in ischaemic cardiogenic shock. Br J Anaesth 2010, 104: 388-389.CrossRefPubMed
21.
Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P: Experimental models of sepsis and their clinical relevance. Shock 2008,30(Suppl 1):53-59. 10.1097/SHK.0b013e318181a343CrossRefPubMed
22.
23.
Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C, Biglioli P, Sala A: Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008, 118: 1612-1618. 10.1161/CIRCULATIONAHA.108.777789CrossRefPubMed
24.
Alcock RF, Roy P, Adorini K, Lau GT, Kritharides L, Lowe HC, Brieger DB, Freedman SB: Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. Int J Cardiol 2010, 140: 66-72. 10.1016/j.ijcard.2008.11.005CrossRefPubMed
25.
Lurati Buse GA, Koller MT, Grapow M, Bolliger D, Seeberger M, Filipovic M: The prognostic value of troponin release after adult cardiac surgery - a meta-analysis. Eur J Cardiothorac Surg 2010, 37: 399-406.PubMed
26.
van Geene Y, van Swieten HA, Noyez L: Cardiac troponin I levels after cardiac surgery as predictor for in-hospital mortality. Interact Cardiovasc Thorac Surg 2010, 10: 413-416. 10.1510/icvts.2009.216408CrossRefPubMed
27.
Paparella D, Scrascia G, Paramythiotis A, Guida P, Magari V, Malvindi PG, Favale S, de Luca Tupputi Schinosa L: Preoperative cardiac troponin I to assess midterm risks of coronary bypass grafting operations in patients with recent myocardial infarction. Ann Thorac Surg 2010, 89: 696-702. 10.1016/j.athoracsur.2009.11.072CrossRefPubMed
28.
Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004, 486: 67-74. 10.1016/j.ejphar.2003.12.005CrossRefPubMed
29.
Toller WG, Stranz C: Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006, 104: 556-569. 10.1097/00000542-200603000-00024CrossRefPubMed
30.
Halpern NA, Pastores SM: Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med 2010, 38: 65-71. 10.1097/CCM.0b013e3181b090d0CrossRefPubMed
31.
Hutchings A, Durand MA, Grieve R, Harrison D, Rowan K, Green J, Cairns J, Black N: Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis. BMJ 2009, 339: b4353. 10.1136/bmj.b4353PubMedCentralCrossRefPubMed
32.
Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002, 4: 515-529. 10.1016/S1388-9842(02)00041-7CrossRefPubMed
33.
Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, Weinbrenner C, Strasser RH: Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008, 36: 2257-2266. 10.1097/CCM.0b013e3181809846CrossRefPubMed
34.
Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, et al.: Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303: 1180-1187.
35.
Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R: Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006, 20: 353-357. 10.1053/j.jvca.2006.02.012CrossRefPubMed
36.
Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O, Bascuas B, Perez-Paz J, Ginesta V: [Hemodynamic effects of levosimendan following cardiac surgery]. Rev Esp Anestesiol Reanim 2005, 52: 389-394.PubMed
37.
Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, Ginesta V, Rubio J, Garcia-Bengoechea JB, Gonzalez-Juanatey JR: [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol 2006, 59: 338-345. 10.1157/13087055CrossRefPubMed
38.
Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D: Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004, 44: 703-708. 10.1097/00005344-200412000-00013CrossRefPubMed
39.
De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ: The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007, 104: 766-773. 10.1213/01.ane.0000256863.92050.d3CrossRefPubMed
40.
De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S, Van der Linden PJ: A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008, 22: 699-705. 10.1053/j.jvca.2008.02.019CrossRefPubMed
41.
De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, Sardella G, Genuini I, Fedele F: Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 2005, 150: 563-568. 10.1016/j.ahj.2004.10.013CrossRefPubMed
42.
Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, Leino KA, Kuitunen AH, Kuttila KT, Peräkylä TK, Sarapohja T, Suojaranta-Ylinen RT, Valtonen M, Salmenperä MT: Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009, 87: 448-454. 10.1016/j.athoracsur.2008.10.029CrossRefPubMed
43.
Husedzinovic I, Barisin S, Bradic N, Barisin A, Sonicki Z, Milanovic R: Levosimendan as a new strategy during off-pump coronary artery bypass grafting: double-blind randomized placebo-controlled trial. Croat Med J 2005, 46: 950-956.PubMed
44.
Jarvela K, Maaranen P, Sisto T, Ruokonen E: Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth 2008, 22: 693-698. 10.1053/j.jvca.2008.01.024CrossRefPubMed
45.
Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, Tanus E, del Mazo CD: [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol 2008, 61: 471-479.CrossRefPubMed
46.
Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenpera M: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998, 19: 660-668. 10.1053/euhj.1997.0806CrossRefPubMed
47.
Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P: Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 2008, 127: 284-287. 10.1016/j.ijcard.2007.04.143CrossRefPubMed
48.
Sonntag S, Sundberg S, Lehtonen LA, Kleber FX: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004, 43: 2177-2182. 10.1016/j.jacc.2004.02.052CrossRefPubMed
49.
Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M, Pietropaoli P: Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth 2006, 96: 694-700. 10.1093/bja/ael082CrossRefPubMed
Metadata
Title
Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials
Authors
Ritesh Maharaj
Victoria Metaxa
Publication date
01-06-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc10263

Other articles of this Issue 3/2011

Critical Care 3/2011 Go to the issue

Letter

ICU survival and the central to mixed venous oxygen difference

Letter

Measurement of monocyte apoptosis, plasma IL-1β and PR3 activity as an approach to evaluate the immunological status in sepsis

Research

Sedation and renal impairment in critically ill patients: a post hoc analysis of a randomized trial

Letter

How natural light affects critically ill patients with subarachnoid hemorrhage

Research

Short term Candida albicans colonization reduces Pseudomonas aeruginosa-related lung injury and bacterial burden in a murine model

Research

Insurance type and sepsis-associated hospitalizations and sepsis-associated mortality among US adults: A retrospective cohort study